ProQR Therapeutics (PRQR)
(Real Time Quote from BATS)
$1.81 USD
+0.03 (1.40%)
Updated Jul 22, 2024 11:56 AM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Price, Consensus and EPS Surprise
PRQR 1.81 +0.03(1.40%)
Will PRQR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PRQR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PRQR
Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock?
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Misses Revenue Estimates
PRQR: What are Zacks experts saying now?
Zacks Private Portfolio Services
GSK (GSK) Q1 Earnings and Revenues Surpass Estimates
Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates
Is ProQR (PRQR) Stock a Solid Choice Right Now?
Other News for PRQR
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
ProQR Shareholders Approve Key Resolutions
ProQR Therapeutics N.V. (PRQR) ASGCT Investor Webcast (Transcript)
Buy Rating Affirmed for ProQR on Promising RNA Editing Technology and Solid Financial Footing
ProQR’s Axiomer Platform Technology Shows Promise: Analyst Maintains Buy Rating on Robust Editing Efficacy and Clinical Development Potential